ZYUS Strengthens Expertise of Clinical Advisory Committee with the Appointment of Dr. Hance Clarke

SASKATOON, Saskatchewan - ZYUS Life Sciences Corporation (the 'Company') (TSX-V: ZYUS), a Canadian-based life sciences company leading scientific research and global development of innovative cannabinoid-based pharmaceutical drug products, today announced the appointment of Hance Clarke, MD, PhD, FRCPC to ZYUS Life Sciences Inc.'s Clinical Advisory Committee.

Dr. Clarke's extensive background in healthcare and pain management aligns seamlessly with the committee's mission to provide valuable insights and strategic guidance to ZYUS' clinical trial programs.

Dr. Clarke is internationally recognized for his outstanding contributions to research productivity and advancements in patient care. He holds the positions of Director of Pain Services at the GoodHope Ehlers Danlos Clinic and the Pain Research Unit at Toronto General Hospital. Additionally, he serves as associate professor in the Department of Anesthesiology and Pain Medicine at the University of Toronto. In his capacity as the Knowledge Translation Chair for the University of Toronto Centre for the Study of Pain, Dr. Clarke demonstrates a strong commitment to advancing the understanding and application of pain research. With over 170 peer-reviewed publications to his credit, he currently holds the position of president-elect of the Canadian Pain Society and serves as the president of the Canadian Consortium for the Investigation of Cannabinoids.

Dr. Clarke has also played a leading role in educating the Canadian public about pain control, risk factors for chronic opioid use, alternatives to opioids and the need for further studies on understanding the beneficial and adverse effects of cannabis. Being a public champion of evidence-based solutions for the opioid crisis and a national pain and addictions strategist, Dr. Clarke's appointment aligns with ZYUS' clinical research initiatives and his influential insights in this field will offer valuable guidance to further enhance ZYUS' clinical programs.

'We are pleased to announce the appointment of Dr. Hance Clarke to the Clinical Advisory Committee,' said Brent Zettl, President and CEO of the Company. 'His deep experience and leadership will provide valuable guidance to our clinical research programs. This strategic addition to our Clinical Advisory Committee reaffirms ZYUS' commitment to advancing non-opioid-based therapies as a viable alternative for managing pain.'

'I am honored to join ZYUS' Clinical Advisory Committee and eager to contribute to ZYUS' important work. Similar to ZYUS, I am passionate about finding non-opioid medication options and improving the lives of patients suffering from chronic pain. Serving on the Clinical Advisory Committee will give me the unique opportunity to provide ZYUS with valuable insights and experience acquired during my career for the purpose of further enhancing its clinical trial programs and improving the lives of patients,' said Dr. Clarke.

Clinical Advisory Committee Members

Dr. Clarke joins previously-appointed Advisory Committee members: ZYUS' Chief Medical Officer, Dr. Lionel Marks de Chabris, Chair of the Committee; Dr. Mary Lynch, Director of Research at the Pain Management Unit at the Queen Elizabeth II Health Sciences Centre; Dr. Cedric Francois, Co-Founder, Chief Executive Officer and President of Apellis Pharmaceuticals; Dr. Alice Zwerling, Assistant Professor in the School of Epidemiology and Public Health in the Faculty of Medicine at the University of Ottawa and Ms. Audrey Haukioja, a seasoned executive with over 25 years of experience in the pharmaceutical field, specializing in clinical trials and drug development.

About the Phase 2 Clinical Trial

Following the Company's announcement on December 5, 2023, ZYUS is moving forward with the decision to fast-track and progress directly to a full Phase 2 Clinical Trial in Canada. This trial aims to evaluate the preliminary efficacy, safety, and tolerability of Trichomylin softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain. Trichomylin softgels, a first-in-class drug product candidate formulated with a proprietary fixed-dose combination, has been specifically designed for the management of chronic pain.

About ZYUS Life Sciences Corporation

ZYUS is a publicly traded Canadian-based life sciences company focused on the global development and commercialization of regulated cannabinoid-based pharmaceutical drug product candidates. Through clinical research, ZYUS is committed to furthering the understanding of cannabinoids with the clinical development of its pharmaceutical drug product candidates and intellectual property activities to protect its novel formulations. Additionally, ZYUS is dedicated to delivering high quality, cGMP/EU GMP-compliant cannabinoid products to patients through the exempt global medical market. The ZYUS vision is to reimagine the potential of pain therapeutics by pursuing regulatory approval of cannabinoid formulations and elevating cannabinoids as a standard of care in pursuit of transformational impact on patients' lives. ZYUS: Advancing the Science of Well-Being.

Cautionary Note Regarding Forward-Looking Statements

This news release contains 'forward-looking information' within the meaning of applicable securities laws relating to the Company's business, the Company's ability to advance clinical research activities, realize on its objectives and obtain regulatory approval of cannabinoid-based pharmaceutical drug product candidates such as Trichomylin softgel capsules, introduce products that act as alternatives to current pain management therapies such as opioids and advance Phase 2 clinical development of Trichomylin softgel capsules. Any such forward-looking statements may be identified by words such as 'expects', 'anticipates', 'intends', 'contemplates', 'believes', 'projects', 'plans' and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the Company's business, the Company's ability to advance clinical research activities, realize on its objectives and obtain regulatory approval of cannabinoid-based pharmaceutical drug product candidates such as Trichomylin softgel capsules, introduce products that act as alternatives to current pain management therapies such as opioids and advance Phase 2 clinical development of Trichomylin softgels are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the Company will be able to advance its clinical research activities and further operations, realize its objectives and obtain regulatory approval of cannabinoid-based pharmaceutical drug product candidates, introduce products that act as alternatives to current pain management therapies such as opioids or advance Phase 2 clinical development of Trichomylin softgels. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law.

Contact:

Email: [e-mail]

Tel: [phone]

(C) 2024 Electronic News Publishing, source ENP Newswire